(2026). FDA Approval of Donanemab‐azbt: A New Dawn in Alzheimer's Disease Treatment. Health Science Reports.
Successfully copied to clipboard
Copying to clipboard failed
Chicago Style (17th ed.) Citation
"FDA Approval of Donanemab‐azbt: A New Dawn in Alzheimer's Disease Treatment."
Health Science Reports 2026.
Successfully copied to clipboard
Copying to clipboard failed
MLA (9th ed.) Citation
"FDA Approval of Donanemab‐azbt: A New Dawn in Alzheimer's Disease Treatment."
Health Science Reports, 2026.
Successfully copied to clipboard
Copying to clipboard failed
Warning: These citations may not always be 100% accurate.